Log In
Print this Print this

IV solithromycin (CEM-101) (formerly OPT-1068)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionIV formulation of a fluoroketolide/macrolide antibiotic
Molecular Target Ribosomal 50S subunit
Mechanism of ActionRibosomal 50S subunit inhibitor
Therapeutic ModalityMacrocycle
Latest Stage of DevelopmentRegistration
Standard IndicationPneumonia
Indication DetailsTreat community-acquired bacterial pneumonia (CABP); Treat moderate to severe community-acquired bacterial pneumonia (CABP)
Regulatory Designation U.S. - Fast Track (Treat community-acquired bacterial pneumonia (CABP))
PartnerCempra Inc.;
Toyama Chemical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today